Shares of Avidity Biosciences (RNA) have increased by 36% over the past month following a report by the Financial Times indicating that Novartis (NVS) is considering an acquisition of the company. The discussions are reportedly at an “early stage” with no assurances of a final deal. Both Avidity and Novartis have not commented on these rumors.
Avidity, based in San Diego, is a clinical-stage biotech focused on RNA therapeutics, with key programs targeting diseases such as myotonic dystrophy and Duchenne muscular dystrophy. In Q2 2025, Avidity reported $3.8 million in collaboration revenue, up from $2 million in the previous year, primarily from its partnership with Bristol Myers.
The potential interest from Novartis is driven by their need to address possible revenue loss from generic competition on some of their top drugs, including Entresto. Novartis aims to enhance its drug pipeline in rare muscular diseases and cardiovascular treatments through acquisitions.
